Immunomedics, Inc. (NASDAQ:IMMU) left investors worried about its cancer asset IMMU-132 after revealing an abstract at yesterday’s annual San Antonio Breast Cancer Symposium that showed overall survival (OS) has since stumbled from data seen in January. Why does Cowen analyst Phil Nadeau remain unfazed?
Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract
